S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20

AbCellera Biologics Stock Forecast, Price & News

-0.45 (-3.12%)
(As of 11/26/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
1.10 million shs
Average Volume
1.70 million shs
Market Capitalization
$3.94 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive ABCL News and Ratings via Email

Sign-up to receive the latest news and ratings for AbCellera Biologics and its competitors with MarketBeat's FREE daily newsletter.

AbCellera Biologics logo

About AbCellera Biologics

AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, AI-powered drug discovery platform searches and analyzes the database of natural immune systems to find antibodies that can be developed as drugs. As of December 31, 2020, the company had 103 discovery programs that are either completed, in progress, or under contract. It has a discovery partnership agreement with Eli Lilly and Company. AbCellera Biologics Inc. was founded in 2012 and is headquartered in Vancouver, Canada.


See More Headlines

Industry, Sector and Symbol

Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$233.15 million


Pretax Margin




Free Float
Market Cap
$3.94 billion
Not Optionable

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

2.37 out of 5 stars

Medical Sector

210th out of 1,391 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.0 5 -4 -3 -2 -1 -

AbCellera Biologics (NASDAQ:ABCL) Frequently Asked Questions

Is AbCellera Biologics a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AbCellera Biologics in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AbCellera Biologics stock.
View analyst ratings for AbCellera Biologics
or view top-rated stocks.

Are investors shorting AbCellera Biologics?

AbCellera Biologics saw a increase in short interest during the month of October. As of October 15th, there was short interest totaling 10,090,000 shares, an increase of 24.3% from the September 30th total of 8,120,000 shares. Based on an average daily volume of 2,410,000 shares, the short-interest ratio is presently 4.2 days. Currently, 6.2% of the company's stock are short sold.
View AbCellera Biologics' Short Interest

When is AbCellera Biologics' next earnings date?

AbCellera Biologics is scheduled to release its next quarterly earnings announcement on Monday, April 4th 2022.
View our earnings forecast for AbCellera Biologics

How were AbCellera Biologics' earnings last quarter?

AbCellera Biologics Inc. (NASDAQ:ABCL) posted its quarterly earnings data on Monday, November, 8th. The company reported ($0.08) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.05) by $0.03. The firm had revenue of $5.51 million for the quarter, compared to analyst estimates of $10.51 million.
View AbCellera Biologics' earnings history

What price target have analysts set for ABCL?

6 Wall Street analysts have issued 1-year target prices for AbCellera Biologics' shares. Their forecasts range from $33.00 to $59.00. On average, they expect AbCellera Biologics' share price to reach $49.00 in the next year. This suggests a possible upside of 250.3% from the stock's current price.
View analysts' price targets for AbCellera Biologics
or view top-rated stocks among Wall Street analysts.

Who are AbCellera Biologics' key executives?

AbCellera Biologics' management team includes the following people:
  • Dr. Carl L.G. Hansen, Pres, CEO & Director (Age 46, Pay $424.68k) (LinkedIn Profile)
  • Dr. Veronique Lecault Ph.D., COO & Director (Age 36, Pay $267.54k) (LinkedIn Profile)
  • Mr. Tryn T. Stimart Esq., J.D., Chief Legal Officer, Chief Compliance Officer & Corp. Sec. (Age 51, Pay $635.63k)
  • Mr. Andrew Booth M.B.A., Chief Financial Officer (Age 47) (LinkedIn Profile)
  • Dr. Ester Falconer Ph.D., Chief Technology Officer (Age 46)
  • Mr. Bo Barnhart Ph.D., Scientific Director
  • Ms. Tiffany Chiu Ph.D., VP of Communications
  • Mr. Murray McCutcheon Ph.D., VP of Corp. Devel.
  • Mr. Kevin Heyries Ph.D., Head of Bus. Devel.

When did AbCellera Biologics IPO?

(ABCL) raised $356 million in an IPO on Friday, December 11th 2020. The company issued 23,000,000 shares at $14.00-$17.00 per share. Credit Suisse, Stifel, Berenberg, SVB Leerink and BMO Capital Markets acted as the underwriters for the IPO.

What is AbCellera Biologics' stock symbol?

AbCellera Biologics trades on the NASDAQ under the ticker symbol "ABCL."

Who are AbCellera Biologics' major shareholders?

AbCellera Biologics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Capital World Investors (7.11%), Allianz Asset Management GmbH (4.26%), Baillie Gifford & Co. (1.16%), Credit Suisse AG (1.01%), Intellectus Partners LLC (0.43%) and BlackRock Inc. (0.35%). Company insiders that own AbCellera Biologics stock include Andrew Booth, Carl L G Hansen, Holdings Ltd Thermopylae, John Hamer, John S Montalbano, Michael R Hayden and Veronique Lecault.
View institutional ownership trends for AbCellera Biologics

Which major investors are selling AbCellera Biologics stock?

ABCL stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Two Sigma Investments LP, Cubist Systematic Strategies LLC, Geode Capital Management LLC, Citadel Advisors LLC, Jump Financial LLC, Tudor Investment Corp Et Al, and Bank of New York Mellon Corp. Company insiders that have sold AbCellera Biologics company stock in the last year include Andrew Booth, Carl L G Hansen, Holdings Ltd Thermopylae, John Hamer, Michael R Hayden, and Veronique Lecault.
View insider buying and selling activity for AbCellera Biologics
or view top insider-selling stocks.

Which major investors are buying AbCellera Biologics stock?

ABCL stock was bought by a variety of institutional investors in the last quarter, including Capital World Investors, Allianz Asset Management GmbH, Millennium Management LLC, Duquesne Family Office LLC, Baillie Gifford & Co., Botty Investors LLC, Gruss & Co. LLC, and Point72 Asset Management L.P.. Company insiders that have bought AbCellera Biologics stock in the last two years include Andrew Booth, Holdings Ltd Thermopylae, and John S Montalbano.
View insider buying and selling activity for AbCellera Biologics
or or view top insider-buying stocks.

How do I buy shares of AbCellera Biologics?

Shares of ABCL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AbCellera Biologics' stock price today?

One share of ABCL stock can currently be purchased for approximately $13.99.

How much money does AbCellera Biologics make?

AbCellera Biologics has a market capitalization of $3.94 billion and generates $233.15 million in revenue each year.

How many employees does AbCellera Biologics have?

AbCellera Biologics employs 206 workers across the globe.

What is AbCellera Biologics' official website?

The official website for AbCellera Biologics is www.abcellera.com.

This page was last updated on 11/28/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.